Bihua Chen is Chief Executive Officer and Chief Investment Officer of Cormorant Asset Management, LP, which the firm's own site says she founded in 2013. She is named in the Helix Acquisition Corp. III IPO prospectus as that company's Chairperson and Chief Executive Officer. SEC ownership filings report her as a director of BlossomHill Therapeutics, Inc. (Form 4, period 6 August 2026), of BridgeBio Oncology Therapeutics, Inc. (Form 4, period 16 June 2026) and of Helix Acquisition Corp. III (Form 3, 22 January 2026, which also records her as an officer with the title Chairperson and CEO). Filings for MoonLake Immunotherapeutics, EyePoint, Inc., Corbus Pharmaceuticals Holdings, Inc. and Bright Minds Biosciences Inc. report her only as a ten percent owner or former ten percent owner alongside the Cormorant funds, not as a director, so those are not recorded as board seats.
Notable Investments
BlossomHill Therapeutics, Inc. BLSMBridgeBio Oncology Therapeutics, Inc. BBOTHelix Acquisition Corp. III HLXC
Board Seats
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), director
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT), director
Helix Acquisition Corp. III (Nasdaq: HLXC), Chairperson and Chief Executive Officer and director
Career Timeline
2013
Founds Cormorant Asset Management in Boston.
2026
Files a Form 3 on 22 January 2026 as Chairperson and CEO and a director of Helix Acquisition Corp. III, whose IPO prospectus was filed the following day.
2026
Files a Form 4 as a director of BridgeBio Oncology Therapeutics, Inc. for the period ended 16 June 2026.
2026
Files a Form 4 as a director of BlossomHill Therapeutics, Inc. for the period ended 6 August 2026.